Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3
| Autor: | Atsumi Sano, Michio Nakamura, Takafumi Sangai, Takahiro Hasebe, Hiroyuki Maeda, Atsushi Ochiai |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty medicine.medical_treatment Blotting Western Estrogen receptor Breast Neoplasms Biology Insulin-like growth factor Breast cancer Somatomedins Cell Line Tumor Internal medicine medicine Humans Aged Aged 80 and over Oncogene Reverse Transcriptase Polymerase Chain Reaction Growth factor Serine Endopeptidases Cancer Kallikrein Middle Aged medicine.disease Insulin-Like Growth Factor Binding Protein 3 Endocrinology Receptors Estrogen Oncology Cancer cell Disease Progression Electrophoresis Polyacrylamide Gel Female |
| Zdroj: | International Journal of Oncology. |
| ISSN: | 1791-2423 1019-6439 |
| Popis: | Expression of human kallikrein 11 (hK11), secreted as a trypsin-like serine protease, is related to the prognosis of some human cancers, but its physiological functions in the steps of cancer progression are still unknown. In order to elucidate the enzymatic function of hK11 we investigated the substrate of hK11 and expression of KLK11, the gene encoding hK11. Among 20 human cancer cell lines tested, two estrogen receptor possessing [ER(+)] breast cancers showed the highest expression of KLK11. The investigation of the hK11 substrate showed that hK11 could degrade itself and insulin-like growth factor (IGF) binding protein 3 (IGFBP-3). Expression of KLK11 was detected in both human breast cancer tissue and in non-cancerous mammary glands, and significantly higher KLK11 expression was observed in histological grade I/II than in grade III breast cancers. The above results indicate that the hK11 expressed in ER(+) breast cancer cells may play a crucial role in breast cancer progression by increasing the bioavailability of IGFs via degradation of IGFBP-3. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|